The Filing Desk

Gossamer Bio vs Protalix BioTherapeutics

Gossamer Bio GOSS · Protalix BioTherapeutics PLX · Biotechnology

Protalix BioTherapeutics reported revenue of $53 million in fiscal 2025, about the same as Gossamer Bio's $48 million in fiscal 2025. Gossamer Bio's revenue fell 57.7% in its latest year, and Protalix BioTherapeutics' fell 1.2%. Gossamer Bio had an operating margin of -352.2%, against -10.4% at Protalix BioTherapeutics. Free cash flow was −$171 million at Gossamer Bio and −$14 million at Protalix BioTherapeutics.

Side by side

Gossamer BioProtalix BioTherapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$48M$53M
Revenue growth−57.7%−1.2%
Revenue growth a year, last 5 years—−3.5%
Gross margin—48.8%
Operating margin−352.2%−10.4%
Net margin−351.5%−12.5%
Free cash flow−$171M−$14M
Free cash flow margin−353.5%−25.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.0%−3.1%
Last close$11.23$3.06
P/E at the last close—12.2×
Insider trades, last 12 months—bought $101,360, sold $0
Piotroski F-score0 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Gossamer BioProtalix BioTherapeutics
Operating margin
Percent of revenue
Gossamer BioProtalix BioTherapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Gossamer BioProtalix BioTherapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Gossamer Bio and Protalix BioTherapeutics pages.